Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
Hmg09Kfrpygr2ZW9
